Determination of the effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19): A randomized, double-blind, placebo-controlled clinical trial study
This is a randomized, placebo-controlled, double-blind parallel-group clinical trial. one hundred participants will randomly allocated to receive curcumin-piperine supplement per day (n = 50) or placebo (n = 50).
Settings and conduct:
In this study, patients with coronavirus will recruited from hospitals of Isfahan University of Medical Sciences. Subjects will stratified according to gender. Random assignment will done by the use of table of random numbers. The enrolling participants, and assigning participants to the groups will carried out by a relevant specialist.The curcumin-piperine supplement and its placebos will be packed in similar boxes, and the researcher and the patients will not be aware of the content of the pack until the end of the study.
Participants/Inclusion and exclusion criteria:
Inclusion criteria: Tendency to participate in the study; People aged 18-65 years; Diagnosis of Covid-19 based on clinical findings and imaging findings (Chest X Ray), CT scan or PCR Exclusion criteria: Age less than 20 and more than 75 years;Taking warfarin; Sensitivity to plant products such as turmeric and pepper
Individuals will randomly assigned to two groups to receive 1000 mg/day curcumin-piperine supplement or placebo for 12 weeks.
Main outcome variables:
CT of the chest, body temperature, length of hospital stay, hs-CRP, ESR, ALT, AST, LDH, BUN, creatinine, CBC, blood oxidative stress indices ( SOD, MDA, TAC), Albumin, Severity of the disease, severity and number of coughs